A-HER2 [4D5, NB9644P28] (ATCC® CRL-10463)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: Hybridoma: B lymphocyte  /  Tissue: Spleen  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Tissue Spleen
Cell Type Hybridoma: B lymphocyte
Product Format frozen
Morphology Lymphoblast-like
Culture Properties Suspension
Biosafety Level 1
Strain BALB/c (B cell); BALB/c (myeloma)
Applications

The antibody binds to the extracellular domain of the HER2 receptor and inhibits the growth of SK-BR-3 (ATCC HTB-30) breast tumor cells. The SK-BR-3 cell line overexpresses the HER2/c-erb-2 gene product.

The antibody prevents HER2/c-erb-2 transformed NIH 3T3 cells from forming colonies in soft agar.

It does not cross-react with the human epidermal growth factor (EGF) receptor and it will immunoprecipiate p185HER2.
Storage Conditions Liquid nitrogen vapor phase
Derivation
Animals were immunized with HER2-amplified NIH 3T3 transformed cells. Spleen cells were fused with P3X63Ag8.653 myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against HER2 receptor
Cellular Products
immunoglobulin; monoclonal antibody; against HER2 receptor
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 105 viable cells/mL.
Interval: Maintain cell density between 5 X 104 and 1 X 106 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
Isotype mouse IgG1
Name of Depositor Genentech, Inc.
References

Hudziak RM, et al. Monoclonal antibodies directed to the Her2 receptor. US Patent 5,677,171 dated Oct 14 1997

Hudziak RM, et al. In vivo tumor detection assay. US Patent 5,720,937 dated Feb 24 1998

Fendly BM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50: 1550-1558, 1990. PubMed: 1689212

Hudziak RM, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9: 1165-1172, 1989. PubMed: 2566907

Baughman SA, Shak S. Dosages for treatment with anti-Erb2 antibodies. US Patent 6,627,196 dated Sep 30 2003

Carter PJ, Presta LG. Method for making humanized antibodies. U.S. Patent 6,800,738 dated Oct 5 2004

Carter PJ, Presta LG. Method for making humanized antibodies . U.S. Patent 6,719,971 dated Apr 13 2004

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Hudziak RM, et al. Monoclonal antibodies directed to the Her2 receptor. US Patent 5,677,171 dated Oct 14 1997

Hudziak RM, et al. In vivo tumor detection assay. US Patent 5,720,937 dated Feb 24 1998

Fendly BM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50: 1550-1558, 1990. PubMed: 1689212

Hudziak RM, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9: 1165-1172, 1989. PubMed: 2566907

Baughman SA, Shak S. Dosages for treatment with anti-Erb2 antibodies. US Patent 6,627,196 dated Sep 30 2003

Carter PJ, Presta LG. Method for making humanized antibodies. U.S. Patent 6,800,738 dated Oct 5 2004

Carter PJ, Presta LG. Method for making humanized antibodies . U.S. Patent 6,719,971 dated Apr 13 2004